Pfizer (PFE) lowered its 2023 sales forecast on waning COVID-19 vaccine demand, but analysts say cost cuts and new drug launches can drive growth. Yahoo Finance Live reports on how low demand for the COVID vaccine could impact Pfizer's cost savings goals heading into 2024. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.